Product Description
Mechanisms of Action: RNA polymerase Inhibitor, RNA Synthesis Inhibitor, Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Greece | Ireland | New Zealand | South Africa
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Mesothelioma|Gastrointestinal Cancer|Breast Cancer|Esophageal Cancer|Lung Cancer|Digestive System Cancer|Sarcoma|Sarcoma, Ewing
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02859415 |
16-C-0152 | P2 |
Terminated |
Sarcoma|Esophageal Cancer|Mesothelioma |
2019-12-06 |
2022-04-06 |
Primary Endpoints|Treatments |
|
NCT01624090 |
12-C-0151 | P2 |
Terminated |
Digestive System Cancer|Lung Cancer|Esophageal Cancer|Breast Cancer|Mesothelioma|Gastrointestinal Cancer |
2019-08-20 |
2020-01-02 |
||
NCT01610570 |
12-C-0135 | P2 |
Terminated |
Sarcoma, Ewing |
2014-05-21 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|